| 251 |
OYSIENDX |
OSIMERTINIB 80 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 0982/23 |
28-JUN-2023 |
27-JUN-2026 |
View |
| 252 |
PABODX |
PALBOCICLIB 125 MG |
CAPSULE |
BOTTLE |
used to treat advanced-stage or metastatic, hormone receptor-positive, HER2-negative breast cancer |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1343/25 |
27-MAY-2025 |
26-MAY-2030 |
View |
| 253 |
PEMIDX |
PEMIGATINIB 4.5 MG |
TABLET |
BOTTLE |
IN ADULT WHO HAVE ALREADY RECEIVED A PREVIOUS TREATMENT TO TREAT A CERTAIN TYPE OF CHOLANGIOCARCINOMA (BILE DUCT CANCER) THAT HAS SPREAD TO NEARBY TISSUES OR OTHER PARTS OF THE BODY AND CANNOT BE REMOVED BY SURGERY |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1023/23 |
10-OCT-2023 |
09-OCT-2026 |
View |
| 254 |
POMMADX |
POMALIDOMIDE 2 MG |
CAPSULE |
BOTTLE |
USED IN COMBINATION WITH DEAMETHASONE TO TREAT MULTIPLE MYELOMA (A TYPE OF CANCER OF THE BONE MARROW) THAT HAS NOT IMPROVED DURING OR WITHIN 60 DAYS OF TREATMENT WITH AT LEAST TWO OTHER MEDICATIONS INCLUDING LENALIDOMIDE AND PROTEASOME INHIBITOR. |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1022/23 |
10-OCT-2023 |
09-OCT-2026 |
View |
| 255 |
POMMADX |
POMALIDOMIDE 4 MG |
CAPSULE |
BOTTLE |
USED IN COMBINATION WITH DEAMETHASONE TO TREAT MULTIPLE MYELOMA (A TYPE OF CANCER OF THE BONE MARROW) THAT HAS NOT IMPROVED DURING OR WITHIN 60 DAYS OF TREATMENT WITH AT LEAST TWO OTHER MEDICATIONS INCLUDING LENALIDOMIDE AND PROTEASOME INHIBITOR. |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1024/23 |
10-OCT-2023 |
09-OCT-2026 |
View |
| 256 |
PONADX |
PONATINIB 15 MG |
FILM COATED TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC PHASE, ACCELERATED PHASE OR BLAST PHASE CHRONIC MYELOID LEUKEMIA THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY OR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA THAT IS REISISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBIOTR THERAPY |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
11 L 1249/24 |
03-DEC-2024 |
02-DEC-2029 |
View |
| 257 |
PONADX |
PONATINIB 45 MG |
FILM COATED TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC PHASE, ACCELERATED PHASE OR BLAST PHASE CHRONIC MYELOID LEUKEMIA THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY OR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA THAT IS REISISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBIOTR THERAPY |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
11 L 1248/24 |
03-DEC-2024 |
02-DEC-2029 |
View |
| 258 |
PRASEDX |
PRALSETINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS PATIENTS WITH METASTATIC RET FUSION POSITIVE NON SMALL CELL LUNG CANCER |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 1157/24 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 259 |
REPODX |
REPOTRECTINIB 40 MG |
CAPSUEL |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1 POSITIVE NON SMALL CELL LUNG CANCER |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1203/24 |
24-SEP-2024 |
23-SEP-2029 |
View |
| 260 |
RITEDX |
RITLECTINIB 50 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF SEVERE ALOPECIA AREATA IN ADULTS AND ADOLESCENTS 12 YEARS AND OLDER |
NULL |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
BIGBEAR PHARMACEUTICAL LAO CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1286/24 |
2025-02-20 |
2030-02-19 |
View |
